Information Provided By: 
Fly News Breaks for February 29, 2016
ENDP
Feb 29, 2016 | 11:53 EDT
Nomura said the pullback in Endo shares is an overreaction to the increased accrual for the legacy AMS mesh product liability and Q4 results. The firm's analyst highlighted that key branded franchises Xiaflex and Voltaren gel delivered record performance in 4Q, while the Par generics business generated ~$359mn of revenues, and 2016 guidance implies the generics business is still growing at a mid-to-high-teens rate. Additionally, the Bebuca launch has the potential to exceed low expectations, adding an additional driver of organic growth.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
